CPHI Proposes 1:20 Reverse Stock Split, Boosts CEO Pay to $241,600

TL;DR

**CPHI's proposed 1:20 reverse stock split is a desperate move to prop up a struggling stock, likely signaling further dilution and a lack of organic growth.**

AI Summary

China Pharma Holdings, Inc. (CPHI) is holding its Annual Meeting on December 30, 2025, to address critical corporate actions including the election of independent directors, the authorization of a reverse stock split at a ratio of up to 1:20, and the amendment of its Amended and Restated 2010 Long-Term Incentive Plan. The company's CEO, Zhilin Li, received a total annual cash compensation of $241,600 for the fiscal year ended December 31, 2024, an increase from $225,600 in salary in 2023, with an additional $16,000 in 'All Other Compensation' for both years. The 2010 Long-Term Incentive Plan has seen multiple amendments, most recently on December 23, 2024, increasing reserved shares by 11,600 (post-split) to a total of 69,600 shares. Significant beneficial owners include Wenlong Zhan with 8.16% (410,000 shares), Yan Yang with 8.96% (450,000 shares), and Kui Lai, Jianying Cai, and Lihua Li each holding 7.96% (400,000 shares). The proposed reverse stock split, if approved, aims to consolidate shares, potentially impacting market perception and compliance with listing requirements.

Why It Matters

The proposed reverse stock split of up to 1:20 for China Pharma Holdings, Inc. is a critical move that could significantly impact CPHI's stock price and market liquidity, potentially helping it meet exchange listing requirements and attract institutional investors. For existing shareholders, this means fewer, but theoretically higher-valued, shares, which could be a double-edged sword depending on market reaction. The continued amendments to the Long-Term Incentive Plan, increasing reserved shares for executive compensation, signal a focus on executive retention and motivation, but also dilute existing shareholder value. In a competitive pharmaceutical market, these corporate governance decisions are crucial for CPHI's long-term viability and investor confidence.

Risk Assessment

Risk Level: high — The proposal for a reverse stock split of up to 1:20 indicates a high risk level, often a last resort for companies facing delisting due to low share price. While it can temporarily boost share price, it doesn't address underlying business fundamentals. The repeated amendments to the 2010 Long-Term Incentive Plan, increasing reserved shares from 8,000 to 69,600 (post-split) by December 23, 2024, also suggest potential dilution for existing shareholders.

Analyst Insight

Investors should carefully evaluate the implications of the proposed 1:20 reverse stock split, as it often precedes further declines if not accompanied by strong operational improvements. Consider reducing exposure to CPHI until there is clear evidence of fundamental business turnaround and sustained profitability, rather than relying on cosmetic stock price adjustments.

Executive Compensation

Key Numbers

• 1:20 — Reverse Stock Split Ratio (Maximum proposed ratio for common stock consolidation)
• $241,600 — Zhilin Li's Total Annual Cash Compensation (For fiscal year ended December 31, 2024, including $16,000 'All Other Compensation')
• $225,600 — Zhilin Li's Salary (For fiscal year ended December 31, 2023)
• 5,022,002 — Shares of Common Stock Outstanding (As of Record Date November 3, 2025)
• 69,600 — Shares Reserved in 2010 Long-Term Incentive Plan (After Amendment No.2 on December 23, 2024)
• 8.96% — Yan Yang's Beneficial Ownership (Largest individual beneficial owner)
• 6.03% — Zhilin Li's Beneficial Ownership (Chairman's ownership percentage)
• December 30, 2025 — Annual Meeting Date (Date of the Annual Meeting of Stockholders)
• November 3, 2025 — Record Date (Date for determining stockholders entitled to vote)
• RMB400,000 — Zhilin Li's Annual Salary (PRC subsidiary) (Under new employment agreement with Helpson expiring December 31, 2029)

Key Players & Entities

• CHINA PHARMA HOLDINGS, INC. (company) — Registrant for DEF 14A filing
• Zhilin Li (person) — Chairman of the Board, President, CEO, Interim CFO
• Wenlong Zhan (person) — Beneficial stockholder with 8.16% ownership
• Yan Yang (person) — Beneficial stockholder with 8.96% ownership
• Kui Lai (person) — Beneficial stockholder with 7.96% ownership
• Jianying Cai (person) — Beneficial stockholder with 7.96% ownership
• Lihua Li (person) — Beneficial stockholder with 7.96% ownership
• Tao Liu (person) — Beneficial stockholder with 5.97% ownership
• Hainan Helpson Medical & Biotechnology Co., Ltd. (company) — Wholly-owned subsidiary and operating entity in PRC
• SEC (regulator) — Securities and Exchange Commission

FAQ

Risk Factors

• Reverse Stock Split Impact on Listing Compliance [high — regulatory]: The proposed reverse stock split of up to 1:20 is intended to consolidate shares. A primary driver for such actions is often to increase the per-share price to meet minimum bid price requirements for continued listing on exchanges like the Nasdaq Capital Market. Failure to maintain these requirements can lead to delisting, significantly impacting liquidity and investor confidence.
• Dependence on PRC Subsidiary Operations [medium — operational]: The company's primary operating entity is Hainan Helpson Medical & Biotechnology Co., Ltd. in the PRC. Zhilin Li's compensation is partly tied to an agreement with this subsidiary, indicating a significant operational reliance. Disruptions in PRC operations, regulatory changes, or labor issues within Helpson could materially affect the company's performance.
• Potential Dilution from Incentive Plan [low — financial]: The 2010 Long-Term Incentive Plan has been amended to increase reserved shares by 11,600 (post-split) to a total of 69,600 shares. While this is a relatively small number compared to the total outstanding shares (5,022,002 as of Nov 3, 2025), future grants could dilute existing shareholders if not managed carefully or if the stock price does not appreciate significantly.
• PRC Labor Law Severance Obligations [medium — legal]: PRC law mandates severance payments upon termination or expiration of employment agreements for Chinese nationals. This includes a calculation based on years of service and average monthly compensation, capped at three times the local average salary. These obligations represent a potential financial liability for the company's PRC subsidiary, Helpson.

Industry Context

China Pharma Holdings operates within the pharmaceutical and biotechnology sector, a highly competitive and regulated industry. The sector is characterized by significant R&D investment, long product development cycles, and stringent regulatory approvals. Companies often face pressure to innovate while managing costs and navigating complex global supply chains and market access challenges.

Regulatory Implications

The proposed reverse stock split suggests CPHI may be facing challenges in meeting stock exchange listing requirements, such as minimum bid price rules. Failure to comply could lead to delisting. Additionally, operating in the PRC subjects the company to evolving healthcare regulations and labor laws, including mandatory severance payments.

What Investors Should Do

1. Review the rationale and potential impact of the proposed 1:20 reverse stock split on share price and liquidity.
2. Evaluate the executive compensation structure, particularly Zhilin Li's total compensation and the terms of her PRC subsidiary employment agreement.
3. Assess the implications of the increased share reserve under the Long-Term Incentive Plan on potential future dilution.
4. Consider the risks associated with PRC operational dependencies and regulatory compliance, including labor law obligations.

Key Dates

• 2025-12-30: Annual Meeting of Stockholders — Key corporate actions, including director elections and a proposed reverse stock split, will be voted upon. Investor participation is crucial.
• 2025-11-03: Record Date — Determines which shareholders are eligible to vote at the Annual Meeting.
• 2024-12-23: Amendment No. 2 to 2010 Long-Term Incentive Plan — Increased the number of shares reserved under the incentive plan by 11,600 (post-split) to 69,600 shares.
• 2025-01-01: Renewal of Zhilin Li's Employment Agreement — Extended Zhilin Li's CEO role at Helpson through December 31, 2029, with an annual salary of RMB400,000.

Glossary

DEF 14A

A proxy statement filing required by the U.S. Securities and Exchange Commission (SEC) for publicly traded companies to solicit shareholder votes. (This document contains critical information about the company's governance, executive compensation, and proposals to be voted on at the annual meeting.)

Reverse Stock Split

A corporate action where a company reduces the total number of its outstanding shares by consolidating them into fewer, proportionally more valuable shares. (CPHI is proposing a ratio of up to 1:20, likely to increase its stock price and meet exchange listing requirements.)

Beneficial Ownership

The actual right to receive income from or direct the voting of a security, regardless of who holds legal title. (Identifies major shareholders like Yan Yang (8.96%) and Wenlong Zhan (8.16%), providing insight into concentrated ownership.)

Long-Term Incentive Plan

A plan designed to reward executives and employees based on long-term company performance, often through stock options or restricted stock units. (CPHI's 2010 plan has been amended, increasing share reserves, which could impact future equity dilution.)

All Other Compensation

Compensation elements not categorized as salary, bonus, or stock awards, which can include perquisites, life insurance premiums, or other benefits. (Zhilin Li received $16,000 in 'All Other Compensation' in both 2023 and 2024.)

Year-Over-Year Comparison

This filing indicates an increase in Zhilin Li's total cash compensation for 2024 to $241,600 from $225,600 in 2023, primarily driven by a higher base salary. The company is also proposing a significant reverse stock split, a measure not detailed in previous filings, suggesting a strategic move to address potential listing compliance issues or market perception. The Long-Term Incentive Plan has seen an amendment to increase share reserves, a detail that may or may not have been present or as significant in prior filings.

Key Financial Figures

• $0.001 — every holder of common stock, par value $0.001 per share, of the Company (the “C
• $100,000 — icer received compensation in excess of $100,000 during the fiscal year ended December 3
• $241,600 — 024, from our U.S. holding company, was $241,600. Payments upon Termination or Change-i
• $5,565 — ompensation of RMB40,000 (approximately $5,565), payable quarterly and Mr. Bennett is
• $16,000 — itled to receive annual compensation of $16,000, payable quarterly, and a warrant to pu
• $0.19 — of common stock at an exercise price of $0.19 per share. As of the date of this repor
• $120,000 — cipant and the amount involved exceeded $120,000; none of our executive officers serve
• $125,000 — lings or engagements were approximately $125,000 for the fiscal year ended December 31,

Filing Documents

• ea0265803-def14a_chinapharma.htm (DEF 14A) — 220KB
• image_001.jpg (GRAPHIC) — 524KB
• image_002.jpg (GRAPHIC) — 160KB
• image_003.jpg (GRAPHIC) — 188KB
• image_004.jpg (GRAPHIC) — 257KB
• 0001213900-25-110882.txt ( ) — 1777KB

SECURITY OWNERSHIP OF CERTAIN

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT The following table sets forth certain information as of November 3, 2025, with respect to the beneficial ownership of our common stock, the sole outstanding class of our voting securities, by (i) any person or group owning more than 5% of each class of voting securities, (ii) each director, (iii) each executive officer and (iv) all executive officers and directors as a group. As of November 3, 2025, an aggregate of 5,022,002 shares of our common stock were outstanding. Name and Address of Beneficial Owners(1)(2) Amount and Nature of Beneficial Percent of Class(3) Directors and Executive Officers Zhilin Li President, Chief Executive Officer, Interim Chief Financial Officer and Chairman of the Board 302,762 6.03 % Heung Mei Tsui Director 18,626 * Yingwen Zhang Director - - Gene Michael Bennett (4) Director - - Baowen Dong Director - - All directors and executive officers as a group (5 persons) 321,388 6.40 % Beneficial stockholders with 5% or more ownership Zhilin Li 302,762 6.03 % Wenlong Zhan 410,000 8.16 % Yan Yang 450,000 8.96 % Kui Lai 400,000 7.96 % Jianying Cai 400,000 7.96 % Lihua Li 400,000 7.96 % Tao Liu 300,000 5.97 % * Represents less than 1%. (1) Pursuant to Rule 13d-3 under the Exchange Act, a person has beneficial ownership of any securities as to which such person, directly or indirectly, through any contract, arrangement, undertaking, relationship or otherwise has or shares voting power and/or investment power or as to which such person has the right to acquire such voting and/or investment power within 60 days. (2) Unless otherwise stated, each beneficial owner has sole power to vote and dispose of the shares and the address of such person is c/o China Pharma Holdings, Inc., 2nd Floor, No. 17 Jinpan Road, Haikou, Hainan Province, People’s Republic of China 570216. (3) In determining the pe

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION Summary of Executive Compensation The following table sets forth information concerning all cash and non-cash compensation awarded to, earned by or paid to our principal executive officer and principal financial officer during the last two fiscal years in all capacities to our Company and our subsidiaries. No other executive officer received compensation in excess of $100,000 during the fiscal year ended December 31, 2024. SUMMARY COMPENSATION TABLE Stock Option Non-Equity Incentive Plan Nonqualified Deferred Compensation All Other Name and Year Salary Bonus Awards Awards Compensation Earnings Compensation Total principal position Ended ($) ($) ($) ($) ($) ($) ($) ($) Zhilin Li 2024 300,000 16,000 316,000 Chairman, Chief Executive Officer 2023 225,600 - - - - - 16,000 241,600 President and interim Chief Financial Officer Employment Agreements Zhilin Li . Hainan Helpson Medical & Biotechnology Co., Ltd., our wholly-owned subsidiary and operating entity in the PRC (“Helpson”), entered into an employment agreement with Ms. Zhilin Li, our Chairman of the Board and Chief Executive Officer, expiring on June 30, 2025. Helpson renewed the agreement with Ms. Li on the same terms as the original agreement on January 1, 2025. The new employment agreement will expire on December 31, 2029. Pursuant to the terms of the new employment agreement, Ms. Li agreed to continue to serve as Helpson’s Chief Executive Officer for a term of five years at an annual salary of RMB400,000. Helpson may adjust Ms. Li’s compensation based upon her production and operating achievement and her technical ability and working performance. Ms. Li’s total annual cash compensation for the fiscal year ended December 31, 2024, from our U.S. holding company, was $241,600. Payments upon Termination or Change-in-Control PRC Law. Under the applicable laws of the PRC, we must pay severance to all emplo

View Full Filing

View this DEF 14A filing on SEC EDGAR